Shufro Rose & CO LLC Regeneron Pharmaceuticals, Inc. Transaction History

Shufro Rose & CO LLC

$1.27 Billion
Q3 2024

A detailed history of Shufro Rose & CO LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Shufro Rose & CO LLC holds 293 shares of REGN stock, worth $221,745. This represents 0.02% of its overall portfolio holdings.

Number of Shares

293

Previous 293 -0.0%

Holding current value

$221,745

Previous $307,000 0.33%

% of portfolio

0.02%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	SELL	$692.45 - $844.37 $34,622 - $42,218	-50 Reduced 14.58%	293 $241,000
Q2 2023 Aug 02, 2023	SELL	$700.03 - $830.35 $70,003 - $83,035	-100 Reduced 22.57%	343 $246,000
Q2 2022 Jul 22, 2022	SELL	$548.35 - $738.84 $8,225 - $11,082	-15 Reduced 3.28%	443 $262,000
Q1 2022 May 09, 2022	SELL	$595.12 - $698.43 $230,906 - $270,990	-388 Reduced 45.86%	458 $320,000
Q4 2021 Jan 27, 2022	BUY	$543.48 - $670.97 $6,521 - $8,051	12 Added 1.44%	846 $534,000
Q2 2021 Jul 28, 2021	BUY	$472.8 - $558.54 $1,891 - $2,234	4 Added 0.48%	834 $466,000
Q4 2020 Feb 03, 2021	BUY	$478.3 - $607.98 $110,009 - $139,835	230 Added 38.33%	830 $401,000
Q4 2019 Jan 28, 2020	BUY	$274.13 - $376.51 $164,478 - $225,906	600 New	600 $225,000
Q2 2019 Jul 24, 2019	SELL	$299.6 - $414.82 $179,760 - $248,892	-600 Closed	0 $0
Q2 2018 Jul 27, 2018	SELL	$284.6 - $344.99 $28,460 - $34,499	-100 Reduced 14.29%	600 $207,000
Q4 2017 Feb 06, 2018	BUY	$358.63 - $469.95 $35,863 - $46,995	100 Added 16.67%	700 $263,000
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $258,828 - $302,400	600	600 $268,000

Others Institutions Holding REGN

# of Institutions

1,529

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shufro Rose & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shufro Rose & CO LLC with notifications on news.

Account

Shufro Rose & CO LLC Regeneron Pharmaceuticals, Inc. Transaction History